BLENREP▼ (Belantamab mafodotin) logo

Product menu

BLENREP is indicated in adults for the treatment of multiple myeloma:1

  • In combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and
  • In combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy including lenalidomide

To support your patients

Image of BLENREP patient booklet

Information for patients prescribed BLENREP ▼ (belantamab mafodotin): A guide to starting treatment

A booklet for your patients who have been prescribed BLENREP to help them understand their treatment, and any possible side effects.

Contact your local representative to request a copy

For prescribers

NA

Get on board with BLENREP ▼ (belantamab mafodotin) at first relapse

Booklet for prescribers describing BLENREP-triplet combinations, the DREAMM-7 and 8 clinical trials, and information to help manage side effects.

Contact your local representative to request a copy

Image of checklist to determine if a patient with RRMM is suitable for BLENREP + Vd

Could your patients with RRMM be eligible for BLENREP in combination with Vd at 2L?

This checklist has been developed to help you determine if your patients with multiple myeloma could be eligible for treatment with BLENREP + Vd.

Contact your local representative to request a copy

For nurses and pharmacists

NA

Help your patients navigate BLENREP ▼ (belantamab mafodotin)

This booklet will help you to support your patients who have been prescribed BLENREP.

Contact your local representative to request a copy

Find your local representative

Image of the map of the UK highlighted different colours to separate regions Image of the map of the UK highlighted different colours to separate regions

Abbreviations

2L, second line; RRMM, relapsed, refractory multiple myeloma; Vd, bortezomib and dexamethasone.

References

  1. BLENREP. Summary of Product Characteristics. GlaxoSmithKline. 2025.

▼This product is subject to additional monitoring. Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or via the Yellow Card app (available on the Apple App Store or Google Play Store). Adverse events should also be reported to GlaxoSmithKline on 0800 221 441 or UKSafety@GSK.com.

September 2025 | PM-GB-BLM-WCNT-250017 (V1.0)